HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.